Connect with us

UK / EU Cannabis Compliance

CBD applications from 7 companies advanced by UK food safety authorities

Published

on


Hemp Today report

A batch of applications for CBD products submitted by a UK trade group has been advanced by food safety authorities.

The Association for the Cannabinoid Industry (ACI), which formed a consortium to represent its members in the approval process, said validation of the applications under two joint dossiers submitted to the Food Standards Agency (FSA) could play a factor in the approval of as many as 4,000 products under 320 brands.

‘Crucial’

“Validation” is the second step in the FSA’s three-step process for approving new (or “novel”) foods.

“Every consortium member’s applications ride on the back of those, so the success of those two (dossiers) is crucial to every other validation,” Tom Risby, ACI’s business R&D manager, told NutritionInsight.

Risby said the products could be moved to the “validated” column on the FSA’s register of CBD products “in the coming days.”

Companies advanced

As of today, products in the two ACI dossiers remain in the FSA’s “awaiting evidence” category on the agency’s public list – the first phase of the approval process. The applications cover 29 isolate and distillate products from seven companies: GenCanna (4); Embody Brands, LLC (6); Global Resource Operations, LLC (8); Janus Organics/Taylor Mammon Ltd (1); Jersey Hemp Ltd (5); Naturecan UK (4); and Standard Hemp (1).

To get onto the public list – and therefore remain on the market pending FSA’s final approval – products already in distribution had to have been on sale before Feb. 13, 2020. Those introduced to the market after that date were not eligible for the agency’s consideration.

The prize

The FSA is in the process of sorting out applications for roughly 12,000 individual products as it works to clarify a flourishing gray market that has seen retail outlets flooded with CBD products over the past several years. ACI has estimated the domestic CBD market at roughly £690 million ($830 million/€785 million).

FSA said it expects the first CBD products to be fully authorized during the latter half of 2023 if the evidence necessary for safety assessments is complete. The authorization process can take more time if additional studies are required, according to the agency.

https://hemptoday.net/cbd-applications-from-7-companies-advanced-by-uk-food-safety-authorities/



Source link

Continue Reading

UK / EU Cannabis Compliance

Denmark Announces Plans for Cannabis Permanent Legal Framework

Published

on

By


Business of Cannabis

Denmark’s six-year medical cannabis pilot scheme could soon be expanded into a fully legalised market, following a surprise announcement from the government last week.

The Danish pilot scheme has been running since 2018, and has continued to expand in both scope and patient numbers over the past six years, with four different access schemes now operating.

Following the publication of a comprehensive analysis of these programmes, Minister of the Interior and Health Sophie Løhde last week met with the parties behind the trial scheme to discuss plans to ‘make the scheme permanent’.

Danish medical cannabis oil producer Stenocare tells Business of Cannabis that while the structure of the new framework is not yet clear, it’s likely to see a significant expansion in the market.

“It is going to grow the market. Medicinal products are primarily prescribed by specialists, while the pilot programme allows medical cannabis to be prescribed by GPs, so their’s a larger pool of prescribers out there… I think we’ll see an increase in treatment,” its CEO Thomas Skovlund Schnegelsberg said.

Read the full report

https://businessofcannabis.com/new-era-for-medical-cannabis-in-denmark-as-government-announces-plans-for-permanent-legal-framework/?utm_content=330050794&utm_medium=social&utm_source=linkedin&hss_channel=lcp-42296127



Source link

Continue Reading

UK / EU Cannabis Compliance

UK: Celeb Big Narstie To Open Medical Cannabis Office In Essex

Published

on

By


High & Polite write

Big Narstie to medical cannabis office in Essex 

Hold onto your spliffs, folks—because Big Narstie is making serious moves in the medical cannabis game!

The grime legend, comedian, and all-around UK icon is turning an old Barclay’s bank in South Woodham Ferrers into his very own medical cannabis office.

Yep, you read that right—Big Narstie Medical is officially open for business, ready to deliver “high-quality medicinal cannabis” to UK patients in need.

Now, we know what some of you might be thinking—“Big Narstie? Medical cannabis?”

But let’s be real, who better to bridge the gap between everyday people and the life-changing potential of medicinal cannabis?

Since the UK legalised medical cannabis in 2018, patients suffering from severe epilepsy, chemo-induced nausea, and MS have found relief through legal weed.

Narstie’s move isn’t just about the clout (though let’s be honest, a medical cannabis office is pretty cool).

He’s shining a much-needed spotlight on the benefits of medical cannabis, especially for those who don’ realise it can be legally prescribed.

So, whether you’re a fan or not, this is one groundbreaking move worth keeping an eye on.

Home



Source link

Continue Reading

UK / EU Cannabis Compliance

German Medical Cannabis Associations Call For Wider Regulatory Reform

Published

on

By


In July 2023, Germany’s federal government commissioned the Federal Joint Committee (G-BA) – the body responsible for determining which medical treatments are covered by the country’s statutory health insurance – to amend the current regulations around medical cannabis prescriptions.

The G-BA is in the process of deciding four specialist areas for which the current approval requirement should no longer apply, making it easier to obtain insurance coverage for the medicine.

However, the country’s medical cannabis associations say this does not go far enough and have called for the approval requirement to be removed for all conditions in which cannabis has shown medical efficacy.

Medical cannabis has been legal in Germany since 2017 and can be prescribed by any doctor for patients with serious medical conditions. It is one of the few countries globally where the treatment can be covered under the public health insurance system in certain cases.

But currently, for patients with statutory health insurance, the costs of medical cannabis are only covered if previously approved by the insurance company.

This application process is said to be ‘daunting, lengthy and bureaucratic’ for doctors and patients, with 30-40% of applications being rejected.

https://businessofcannabis.com/german-medical-cannabis-associations-call-for-wider-regulatory-reform/



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media